Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar(Amsterdam Neuroscience), Diederik van de Beek(Amsterdam Neuroscience), Janneke Horn(Amsterdam UMC Location University of Amsterdam), Frederique Paulus(Amsterdam University Medical Centers), Marcus J. Schultz(Academic Medical Center), E. Marleen Kemper(Amsterdam University Medical Centers), Iwan C.C. van der Horst(Maastricht University Medical Centre), W. Joost Wiersinga(Amsterdam University Medical Centers), Liora ter Horst(Amsterdam Neuroscience), Matthias H. Busch(Maastricht University Medical Centre), Ingeborg E. van Zeggeren(Amsterdam Neuroscience), Simon Rueckinger, Korinna Pilz(Inflarx (Germany)), Martin Witzenrath, Lieuwe D. J. Bos(Amsterdam University Medical Centers), Leo Heunks(Amsterdam University Medical Centers), Sjoerd A.M.E.G. Timmermans(Maastricht University Medical Centre), Esther Bulle(Amsterdam University Medical Centers), Rutger Koning(Amsterdam Neuroscience), Marcel C.G. van de Poll(Maastricht University Medical Centre), Niels C. Riedemann(Jena University Hospital), Sanne de Bruin(Amsterdam University Medical Centers), Frank E.H.P. van Baarle(Amsterdam University Medical Centers), Pieter van Paassen(Maastricht University Medical Centre), Ren-Feng Guo(University of Michigan), Matthijs C. Brouwer(Amsterdam Neuroscience)
Cited by 199
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.7k